Lancet Respiratory Medicine

Article	Citations
Savolitinib in NSCLC: progress in the MET exon 14 journey	535
Broad protection from SARS-CoV-2 variants without antigen matching	330
European Respiratory Society International Congress 2022	268
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	264
Opioids bring peace to patients with IPF cough	248
Impact of Myanmar's earthquake on respiratory health	245
Predatory publishers appear in PubMed (and your inbox)	240
FLiRTing with danger as SARS-CoV-2 variants evolve	232
Thoracentesis: an old story and some new sources	217
Chronic obstructive pulmonary disease: 10 years of precision-guided success	214
Correction to Lancet Respir Med 2024; 12: 129–40	208
Interstitial lung disease: a decade of progress and hope	202
Concerns about PRISm	201
The burden of tuberculosis in Libya	201
Rituximab for connective tissue disease-associated interstitial lung disease	198
Long COVID: systemic inflammation and obesity as therapeutic targets	198
Rethinking the role of procalcitonin in suspected sepsis	190
Major gaps in childhood pneumonia research priorities remain	190
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	188
US Senate committee investigates asthma inhaler prices	187
Australia bans engineered stone to prevent silicosis	178
Video laryngoscopy is not the nemesis of direct laryngoscopy	177
Predicted bodyweight—a misleading metric for tidal volume titration?	174
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	168
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	167

Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop	162
Concerns regarding a suggested long COVID paradigm – Authors' reply	159
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros	158
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	154
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	149
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	148
Chronic respiratory diseases in Asia: time for action	147
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	138
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	137
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	136
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	134
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	132
Claudio Castanos—leader in cystic fibrosis care in Argentina	131
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	128
Solid and semi-solid perspectives in thoracic surgery	127
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	126
Genetic associations and lung function in IPF: unexpected answers, persistent questions	123
Extracorporeal cardiopulmonary resuscitation: not why, but how	122
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	119
Trump administration decimates worker health oversight	118
Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial	115
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	115
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, m	115
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	114
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	110
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	110
Sphaerosymphony: turning air quality data into music	110
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	109
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	109
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	109
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis	108
Correction to Lancet Respir Med 2022; 10: 972–84	107
Correction to Lancet Respir Med 2021; 9: 1275–87	105
Correction to Lancet Respir Med 2025; 13: 244–55	102
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts	101
Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysis	101
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	101
Association of SARS-CoV-2 infection and persistence with long COVID	100
Chronic cough as a disease: implications for practice, research, and health care	99
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	98
Health effects from climate-driven events: lessons learnt	97
Spirometry in female individuals – Authors' reply	96
Choice overload for RSV prevention—how to form your opinion	96
The Ramp to Nowhere: When hope slips through the cracks in care	95
Developments and priorities in bronchiectasis research	95
US lung cancer report suggests years of encouraging progress under threat from health agency cuts	94
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration	92
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing	92
Realignment of clinical research after the COVID-19 era	92
Tackling tuberculosis: what lies beneath the surface?	90

NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	89
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	88
COP27 Climate Change Conference: urgent action needed for Africa and the world	87
Liberal or restrictive transfusion for VV ECMO	84
Underappreciated causes of obstructive lung disease	84
Clean air, climate targets, and respiratory health in Europe	79
Russell Winwood: “COPD Athlete” defying views on lung disease	79
Real-time subphenotyping in acute respiratory distress syndrome: a step towards precision medicine	77
Pooled testing for TB: revisiting a cost-saving innovation	73
Correction to Lancet Respir Med 2023; 11: 1064–74	72
Unveiling a hidden phenotype of early tuberculosis	72
Opioid use and sleep apnoea	70
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic	69
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	69
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial	69
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study	68
Trouble with promoting lung cancer screening in never-smokers	68
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot	68
Early-life respiratory syncytial virus disease and long-term respiratory health	67
Pre-COPD: an evolving concept with practice potential	67
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial	67
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study	66
Pulmonary hydatid disease in children: a neglected burden hidden in plain sight	66
Collateral caring	66
The recent explosion in snortable energy powder consumption	64
Treating acute respiratory illness: the need to be proactive	64
Society of Critical Care Medicine Critical Care Congress 2023	64
E-cigarette company tactics in sports advertising	63
COVID-19—an infectious disease in the top five causes of death in Australia	62
SIMPLIFYing cystic fibrosis treatment in a post-modulator era	62
Correction to Lancet Respir Med 2022; published online Feb 25. https://doi.org/10.1016/S2213-2600(22)00045-5	62
Breathing barriers: bridging lung health, research, and awareness	62
Combined SHP2 and KRASG12C inhibitor therapy in patients with non-small-cell lung cancer	61
Beyond the ventilator: rethinking daily evaluation of respiratory drive and effort	61
Wildfires in southern California: concerns for lung health	60
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial	60
Home monitoring in interstitial lung diseases	60
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	59
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial	59
Pioneering a paradigm shift in asthma management: remission as a treatment goal	59
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement	57
Where fresh air fails: COPD and the hidden burden of coastal living	57
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial	57
The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial	57
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study	57
Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational,	57
A benchmarking study and roadmap for sepsis: who dies from septic shock?	56
Managing tuberculosis before the onset of symptoms	56
US EPA backs industry lawsuit to undo its own work on air pollution rule	56
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from tw	56
Assessing the reversibility of bronchiectasis with deep learning	56
Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PR	55
Trial emulation with observational data in cystic fibrosis	54
NUTRIREA-3: where to next?	54
Sanjay Ramakrishnan—several lucky turns to arrive at COPD	54
Correction to Lancet Respir Med 2025; 13: 800–08	53
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab	51
Moving forward in IPF: lessons learned from clinical trials	50
EVEREST and the eosinophil paradox – Authors' reply	50
What is adequate preoxygenation? – Authors' reply	48
The importance of post-tuberculosis morbidity in high-income countries	48
Rethinking bronchiectasis through a metabolic lens	47
Rise in group A streptococcal infections in England	47
Tackling the global burden of lung disease through prevention and early diagnosis	47
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multi	47
Non-invasive respiratory support improves outcomes in high-income countries	47
Remission in chronic cough: an achievable target?	47
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	46
Continuing ECMO with no possible transition to recovery or transplant	45
Common and rare variants and survival in idiopathic pulmonary fibrosis	45
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies	44
JCOG0802 and CALGB140503: the gap between trial design and clinical application	44
General population-based lung function trajectories over the life course: an accelerated cohort study	44
2026 GINA report for asthma	44
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled c	43
Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial	42
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	42
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	41
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicent	40
Perioperative lung expansion and pulmonary outcomes after abdominal surgery	39

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial	39
Use of lung-cancer trends for global and public health priorities	38
European Lung Cancer Congress 2024	38
Reflections 5 years on from the approval of ETI therapy	38
Guidelines might help reduce the burden of asthma in African children	37
Flavia Machado—a Latin American leader in sepsis	37
Stubble: the Farmer's Bane	37
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO – Authors' reply	37
Community-acquired pneumonia: the best candidates for clarithromycin	36
US Senate announces planned gun reforms after latest school shooting	36
Neomi Shah—cracking the conundrum of sleep disorders	36
Lifting the veil on humour and anaesthetics	36
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab	36
The upcoming influenza season and protection from vaccines	36
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	34
International guideline recommendations and eligibility criteria for home oxygen therapy	34
Surviving sepsis with multiple serious complications	34
Correction to Lancet Respir Med 2023; published online Feb 3. https://doi.org/10.1016/S2213-2600(22)00491-X	34
Correction to Lancet Respir Med 2024; 12: 544–55	34
Ventilation during surgery: moving away from one-size-fits-all	32
Fighting sepsis: still a long way to go	32
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally	32
How early should CFTR modulators be initiated to prevent structural cystic fibrosis lung disease?	32
Oral corticosteroids for acute preschool wheeze	32
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised,	31
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial	31
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial	31
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts	31
ECMO: more than just a bridge over troubled waters?	31
Management of prematurity-associated lung disease from infancy through to adulthood	31
When evidence is not enough: making videolaryngoscopy the default for tracheal intubation	30
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management	30
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	30
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study	30
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	30
Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlle	29
Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial	29
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	28
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply	28
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	28
Concerns regarding a suggested long COVID paradigm	27
Discussions on VT4COVID	27
The carbon footprint of inhaled medications in Australia	26
Correction to Lancet Respir Med 2025; 13: 318–26	26
Lockdown as the mother of invention: disruptive technology in a disrupted time	26
Correction Lancet Respir Med 2022; 10: 937–48	26
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation	25
Continued resuscitation at the scene versus early transport for refractory out-of-hospital cardiac arrest	25
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply	25
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients	25
Remdesivir saves lives. Were 3 years needed to learn that?	25
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents	25
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	25
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	25
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial	24
US EPA strengthens PM2·5 air pollution limits	24
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	24
Home-based monitoring in chronic respiratory diseases: in search of Panacea	24
Air pollution, climate change, and lung health in Europe	24
Tuberculosis prevalence: beyond the tip of the iceberg	23
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	23
How Glasgow's 1957 tuberculosis screening programme could help countries today	23
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	22
Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX): a multicentre, randomised, sham-controlled trial	22
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	22
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 tria	22
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply	21
Neurofilament light chain in post-cardiac arrest prognostication: from signal to strategy	21
Living with spinal muscular atrophy while working in critical care	21
European Respiratory Society International Congress 2024	20
What is next for BCG revaccination to prevent tuberculosis?	20
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	20
Treatment strategy for EGFR mutated NSCLC	20
Navigating uncertainty: asthma biologics during pregnancy	20
Add-on LAMA therapy in asthma: an underused strategy for exacerbation prevention	20
Addressing the origins and health effects of small lungs	20
Sedative medications: an avoidable cause of asthma and COPD exacerbations?	19
D-dimer thresholds in pulmonary embolism: avoiding one-size-fits-all	19
The Wuhan lockdown	19
Opportunities and challenges of COPD tertiary prevention	19
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa	19
Can the positive findings from POD1UM-304 improve patient care worldwide?	19
Phenotypes of idiopathic pulmonary arterial hypertension	19
Tuberculosis, conflict, and displacement	19
Chronic obstructive pulmonary disease: new therapies and old needs	18
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open	18
Implementing endotoxin adsorption for septic shock into clinical practice	18
The future of paediatric acute respiratory distress syndrome	18
Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise	18
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study	18
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, rando	17
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials	17
Idiopathic inflammatory myopathies related lung disease in adults	17
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study	17
Systematic endoscopic staging of mediastinum in locally advanced NSCLC: a SEISMIC change?	17